Resource data sheet
Prev.
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pENTER-EGFR C797S/del19

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.

Catalog number RDB15491
Resource name pENTER-EGFR C797S/del19
Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, C797S and deletion in exon 19, EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.
Comment cDNA was obtained from HCC-827 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor|Developer Katayama, Ryohei |
Other clones in our bank

External Database
human EGFR

          Reference sequence
            

          Distribution information

          Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
          Terms and conditions set forth by the DEPOSITOR In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
          Ordering Please visit Information of Request for Distribution.[link] 
          Order form 
          [Credit Card Payment]  [Bank Transfer Payment]
          Material Transfer Agreement (MTA for use for not-for-profit academic purpose) [Word]
          Remarks
          Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
          提供案内 (日本国内) [open/close]

          提供条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
          提供依頼 手続きの詳細は、「提供申込みについて[link]」をご覧ください。
          提供依頼書 [Word]
          提供同意書 (MTA、非営利機関による非営利学術研究用)[Word]
          備考
          Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

          Catalog # Resource name Shipping form Fee (non-profit org.)
          RDB15491 pENTER-EGFR C797S/del19 DNA solution

          Please review the QC test results indicated by check icon below as well as clone information before placing your order.

          References and tips

          Electronic file

          Original reference

          original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

          Further references such as user reports and related articles (go to bottom)

          Featured content


          Sequence information

          RIKEN BRC has sequenced portions of this material for quality test.
          Please review the QC test results indicated by check icon as well as clone information before placing your order.

          Test sheet RDB15491_A7K8p1-1.pdf check

          Nucleotide sequence of a portion of this resource (if available).

          Primer: rrnBT1ter_F2
          Region: rrnB T1 ter, attL1, insert 5'
          Sequence file: RDB15491_A7K8a.seq check
          >D04925A4_A7K8_2_rrnBT1ter_F2_D04_10_ABI24.ab1
              1 AGACAGGTCT TCCGACTGAG CCTTTCGTTT TATTTGATGC CTGGCAGTTC CCTACTCTCG
             61 CGTTAACGCT AGCATGGATG TTTTCCCAGT CACGACGTTG TAAAACGACG GCCAGTCTTA
            121 AGCTCGGGCC CCAAATAATG ATTTTATTTT GACTGATAGT GACCTGTTCG TTGCAACAAA
            181 TTGATGAGCA ATGCTTTTTT ATAATGCCAA CTTTGTACAA AAAAGCAGGC TCCGCGGCCG
            241 CCCCCTTCAC CATGCGACCC TCCGGGACGG CCGGGGCAGC GCTCCTGGCG CTGCTGGCTG
            301 CGCTCTGCCC GGCGAGTCGG GCTCTGGAGG AAAAGAAAGT TTGCCAAGGC ACGAGTAACA
            361 AGCTCACGCA GTTGGGCACT TTTGAAGATC ATTTTCTCAG CCTCCAGAGG ATGTTCAATA
            421 ACTGTGAGGT GGTCCTTGGG AATTTGGAAA TTACCTATGT GCAGAGGAAT TATGATCTTT
            481 CCTTCTTAAA GACCATCCAG GAGGTGGCTG GTTATGTCCT CATTGCCCTC AACACAGTGG
            541 AGCGAATTCC TTTGGAAAAC CTGCAGATCA TCAGAGGAAA TATGTACTAC GAAAATTCCT
            601 ATGCCTTAGC AGTCTTATCT AACTATGATG CAAATAAAAC CGGACTGAAG GAGCTGCCCA
            661 TGAGAAATTT ACAGGAAATC CTGCATGGCG CCGTGCGGTT CAGCAACAAC CCTGCCCTGT
            721 GCAATGTGGA GAGCATCCAG TGGCGGGACA TAGTCAGCAG TGACTTTCTC AGCAACATGT
            781 CGATGGACTT CCAGAACCAC CTGGGCAGCT GCCAAAAGTG TGATCCAAGC TGTCCCAATG
            841 GGAGCTGCTG GGGTGCAGGA GAGGAGAACT GCCAGAAACT GACCAAAATC ATCTGTGCCC
            901 AGCAGTGCTC CGGGCGCTGC CGTGGCAAGT CCCCCCAGTG ACTGCTGCCA CAACCAGTGT
            961 GCTGCAGCTG CACAGGCCCC CCGGGGAGAG CGACTGCCTG GTCTGCCGCA AATTCCGAGA
           1021 CGAAGCCACG TGCAAGGACA CCTGCCCCCC CCACTCATGC TCTACACCCC CCACCCACGT
          1081 ACAGAATTGA TGGTGCACCC GAAGGGCCAA AATAACAGCC TTTTTGGGGG TGTCA
          //
          Primer: pDONR_R
          Region: attL2, insert 3'
          Sequence file: RDB15491_A7K8b.seq check
          >D04925A4_A7K8_2_pDONR_R_D08_11_ABI24.ab1
              1 GGGGACGTCA GGGACGCTAT GACCATGTAA TACGACTCAC TATAGGGGAT ATCAGCTGGA
             61 TGGCAAATAA TGATTTTATT TTGACTGATA GTGACCTGTT CGTTGCAACA AATTGATAAG
            121 CAATGCTTTC TTATAATGCC AACTTTGTAC AAGAAAGCTG GGTCGGCGCG CCCACCCTTT
            181 CATGCTCCAA TAAATTCACT GCTTTGTGGC GCGACCCTTA GGTATTCTGC ATTTTCAGCT
            241 GTGGAGCCCT TAAAGATGCC ATTTGGCTTG GCTTCCTTGG GAAAGAAGTC CTGCTGGTAG
            301 TCAGGGTTGT CCAGGCTAAT TTGGTGGCTG CCTTTCTGGG CCCAGTGGGC AGGGCTGTCG
            361 AATGTGCTGT TGACACAGGT GGGCTGGACA GTGTTGAGAT ACTCGGGGTT GCCCACTGCA
            421 GTGCTGTGGG GGTCCTGGTA GTGTGGGTCT CTGCTGGGCG CGGGGTTCAG AGGCTGATTG
            481 TGATAGACAG GATTCTGCAC AGAGCCAGCG GGCCTTTTGG GAACGGACTG GTTTATGTAT
            541 TCAGGCACTG GGAGGAAGGT GTCGTCTATG CTGTCCTCAG TCAAGGCGCC TGTGGGGTCT
            601 GAGCTGTATC GCTGCAAGAA GCTGTCTTCC TTGATGGGAC AGCTTTGCAG CCCATTTCTA
            661 TCAATGCAAG CCACGGTGGA ATTGTTGCTG GTTGCACTCA GAGAGCTCAG GAGGGGAGTC
            721 CGTGACGTGG AGGGGCTGCT GAAGAAGCCC TGCTGTGGGA TGAGGTACTC GTCGGCATCC
            781 ACCACGTCGT CCATGTCTTC TTCATCCATC AGGGCACGGT AGAAGTTGGA GTCTGTAGGA
            841 CTTGGCAAAT GCATTCTTTC ATCCCCCTGA ATGACAAGGT AGCGCTGGGG GGTCTCGGGC
            901 CATTTTGGAG AATTCGATGA TCAACTCACG GAACTTTGGG CGACTATCTG CGTCTATCAT
            961 CCAGCACTTG ACCATGATCA TGTAGACATC GATGGTACAT ATGGGTGGCT GAGGAGGCGT
           1021 TTCTCCTTTC TCCAGGATGG GAGGAGATCT CGGCTGGGCA AGGATTCCCG CTCATATGAC
          1081 TGGAATTCGA AGATCATCAA CCTCCCCAAA ACCAGT
          //
          Primer: EGFR-F5
          Region: insert middle region (C797S, del19)
          Sequence file: RDB15491_A7K8c.seq check
          >D04925A4_A7K8_2_EGFR-F5_D09_12_ABI24.ab1
              1 ACCTTATCGT CATCGCCACT GGGATGGTGG GGGCCCTCCT CTTGCTGCTG GTGGTGGCCC
             61 TGGGGATCGG CCTCTTCATG CGAAGGCGCC ACATCGTTCG GAAGCGCACG CTGCGGAGGC
            121 TGCTGCAGGA GAGGGAGCTT GTGGAGCCTC TTACACCCAG TGGAGAAGCT CCCAACCAAG
            181 CTCTCTTGAG GATCTTGAAG GAAACTGAAT TCAAAAAGAT CAAAGTGCTG GGCTCCGGTG
            241 CGTTCGGCAC GGTGTATAAG GGACTCTGGA TCCCAGAAGG TGAGAAAGTT AAAATTCCCG
            301 TCGCTATCAA GACATCTCCG AAAGCCAACA AGGAAATCCT CGATGAAGCC TACGTGATGG
            361 CCAGCGTGGA CAACCCCCAC GTGTGCCGCC TGCTGGGCAT CTGCCTCACC TCCACCGTGC
            421 AACTCATCAC GCAGCTCATG CCCTTCGGCT CCCTCCTGGA CTATGTCCGG GAACACAAAG
            481 ACAATATTGG CTCCCAGTAC CTGCTCAACT GGTGTGTGCA GATCGCAAAG GGCATGAACT
            541 ACTTGGAGGA CCGTCGCTTG GTGCACCGCG ACCTGGCAGC CAGGAACGTA CTGGTGAAAA
            601 CACCGCAGCA TGTCAAGATC ACAGATTTTG GGCTGGCCAA ACTGCTGGGT GCGGAAGAGA
            661 AAGAATACCA TGCAGAAGGA GGCAAAGTGC CTATCAAGTG GATGGCATTG GAATCAATTT
            721 TACACAGAAT CTATACCCAC CAGAGTGATG TCTGGAGCTA CGGGGTGACC GTTTGGGAGT
            781 TGATGACCTT TGGATCCAAG CCATATGACG GAATCCCTGC CAGCGAGATC TCCTCCATCC
            841 TGGAGAAAGG AGAACGCCTC CCTCAGCCAC CCATATGTAC CATCGATGTC TACATGATCA
            901 TGGTCAAGTG CTGGATGATA GACGCAGATA GTCGCCCAAA GTTCCGTGAG TTGATCATCG
            961 AATTCTCCAA AATGGCCCGA GACCCCCAGC GCTACCCTTG TCATTCACGG GGGATGAAGA
           1021 TGCATTTGCC AAGTCCTACA GACTCTAACT TTCTACCGTG CCCCTGATCA TGGAAGGAGA
          1081 CATGGGACGA ACGTTGGATT GGAATTGGCC GGACG
          //

          Please visit Sequencing and PCR primers for primer information.


          References

          Original, user report and related articles

          original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

          2022.05.17

          GNP_filter3_RDBDEP_html_220516.pl